Publicaciones en las que colabora con JOSE MARIA PASCUAL IZUEL (39)

2018

  1. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529

2014

  1. Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: A multicenter, randomized, double-blind study

    Blood Pressure, Vol. 23, Núm. 3, pp. 181-188

  2. Impact of abdominal obesity and ambulatory blood pressure in the diagnosis of left ventricular hypertrophy in never treated hypertensives

    Medicina Clinica, Vol. 142, Núm. 6, pp. 235-242

  3. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension

    Hypertension, Vol. 64, Núm. 6, pp. 1228-1234

2013

  1. Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment

    Journal of Hypertension, Vol. 31, Núm. 8, pp. 1683-1691

2009

  1. Body weight variation and control of cardiovascular risk factors in essential hypertension

    Blood Pressure, Vol. 18, Núm. 5, pp. 247-254

  2. European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2008; 9: No. 36. Mikroalbuminurie bei essenzieller hypertonie

    Journal fur Hypertonie, Vol. 13, Núm. 3, pp. 31-33

2008

  1. Added impact of obesity and insulin resistance in nocturnal blood pressure elevation in children and adolescents

    Hypertension, Vol. 51, Núm. 3, pp. 635-641

2007

  1. Factores determinantes de la reducción de la excreción urinaria de albúmina en la hipertensión arterial esencial

    Hipertension

2006

  1. Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study

    Journal of Hypertension, Vol. 24, Núm. 11, pp. 2277-2284

  2. Development of microalbuminuria in essential hypertension

    Current Hypertension Reports, Vol. 8, Núm. 2, pp. 171-177

2005

  1. Estudio doble ciego de la eficacia y la seguridad de la combinación a dosis fija de 10 mg de enalapril/20 mg de nitrendipino en comparación con el incremento de dosis de amlodipino en pacientes con hipertensión esencial no controlada con 5 mg de amlodipino

    Revista Clinica Espanola, Vol. 205, Núm. 9, pp. 418-424

  2. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension

    Hypertension, Vol. 45, Núm. 6, pp. 1125-1130

2004

  1. Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: A 3-year follow-up study

    Journal of Human Hypertension, Vol. 18, Núm. 1, pp. 25-31

2002

  1. Body weight changes and the A-6G polymorphism of the angiotensinogen gene

    International Journal of Obesity, Vol. 26, Núm. 9, pp. 1173-1178

  2. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension

    Hypertension, Vol. 39, Núm. 3, pp. 794-798

  3. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes

    New England Journal of Medicine, Vol. 347, Núm. 11, pp. 797-805

2001

  1. Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension

    American Journal of Hypertension, Vol. 14, Núm. 4 I, pp. 364-370

  2. Polymorphism insertion/deletion of the ACE gene and ambulatory blood pressure circadian variability in essential hypertension

    Blood Pressure Monitoring, Vol. 6, Núm. 1, pp. 27-32

  3. Renin-angiotensin system genetic polymorphisms and essential hypertension in the Spanish population

    Medicina Clinica, Vol. 117, Núm. 14, pp. 525-529